Laboratory-confirmed respiratory tract infections

There is 1 paper on laboratory-confirmed respiratory tract infections in aging research: 1 trial in people.

Disease

1 paper studies it3 findings

See all 1 papers on laboratory-confirmed respiratory tract infections

  • Human trial1

Interventions

2

Dactolisib

downin humans1

1 study
  1. Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (OR 0·601 [90% CI 0·391–0·922]).

    “In this analysis we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”

    Human trial10 mg once daily16 weeks

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

  2. Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (phase 2b trial, pooled analysis of parts 1 and 2) (19% vs 28%; OR 0·601 (90% CI 0·391-0·922); p=0·02).

    “we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”

    Human trialphase 2b trial, pooled analysis of parts 1 and 210 mg once daily16 weeks

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

More on Dactolisib

RTB101 + everolimus

no changein humans1

1 study
  1. RTB101 + everolimus showed no clear effect on laboratory-confirmed respiratory tract infections in humans.

    “RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0·1 mg once daily were not associated with a significant reduction in the incidence of laboratory-confirmed RTIs as compared with placebo (data not shown).”

    Human trial10 mg plus everolimus 0·1 mg once daily16 weeks

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

More on RTB101 + everolimus

Latest